Follow the Alignment Healthcare, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Alignment Healthcare, Inc. has logged 361 public disclosures. Market capitalisation: €4.9bn. The latest transaction was disclosed on 2 July 2026 (Attribution). Among the most active insiders: Maroney Dawn Christine. Every trade is openly available.
Analysts rate Alignment Healthcare, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$24.92.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 361 declarations
Alignment Healthcare, Inc. is a U.S.-based healthcare services company listed on the NASDAQ under the ticker ALHC, and its operating footprint is in the United States. The company was founded in 2013 with the stated mission of improving healthcare for seniors by addressing the fragmentation and complexity of the U.S. care system. Its headquarters are in Orange, California, in the Los Angeles area. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832466/000162828026027060/alhc-annualreportfy2025.pdf?utm_source=openai)) At the center of the business is a next-generation, consumer-centric and clinically focused platform built primarily for Medicare beneficiaries, especially those enrolled in Medicare Advantage plans. Alignment Healthcare combines insurance, care coordination, and clinical support into an integrated model designed to simplify the senior healthcare journey. Management emphasizes the use of data and technology to improve access to care, close care gaps, and reduce avoidable hospital utilization, which is a key part of the company’s value proposition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832466/000162828026027060/alhc-annualreportfy2025.pdf?utm_source=openai)) From a competitive standpoint, Alignment Healthcare is a specialized Medicare Advantage player competing against both large diversified managed-care insurers and other focused senior-health platforms. Its differentiation lies in its tightly integrated care model, local provider coordination, and member experience. In its 2025 annual report, the company disclosed approximately 275,300 health plan members at year-end 2025 and operations across 45 markets in 5 states, highlighting strong growth but also a still-concentrated geographic base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832466/000162828026027060/alhc-annualreportfy2025.pdf?utm_source=openai)) The company’s key offerings include HMO and PPO Medicare Advantage plans marketed under the Alignment Health Plan brand. Beyond the insurance wrapper, the product proposition is built around easier access to care, better physician coordination, and support services tailored to seniors across home, digital, and community settings. For investors, the main strategic questions remain execution on membership growth, medical cost control, and margin expansion within a highly regulated U.S. Medicare environment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1832466/000162828026027060/alhc-annualreportfy2025.pdf?utm_source=openai)) Recent developments point to solid operating momentum. Alignment Healthcare reported full-year 2025 results in early 2026 showing continued membership and revenue growth, and it followed with first-quarter 2026 results at the end of April 2026 that management described as strong, with disciplined growth and margin expansion. The company also updated or raised parts of its 2026 outlook in recent communications, suggesting improved confidence in the operating trajectory. As a NASDAQ-listed U.S. healthcare company, it is also worth monitoring SEC Form 4 insider transactions, which can provide useful context but should not be interpreted in isolation. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/02/26/3246044/0/en/alignment-healthcare-reports-fourth-quarter-and-full-year-2025-results-beats-high-end-of-guidance-across-all-key-metrics.html?utm_source=openai))